Researchers studying ovarian cancer (above) developed the drug Nanotax, which is in clinical trials as a treatment for the devastating disease. Dr. Roy Jensen (top) is director of the KU Cancer Center at the KU Medical Center. It coordinates treatment and research collaborations with six Kansas hospitals, Kansas State University, and four hospitals in Kansas City, Mo.
NEW DRUGS FOR CANCER
Hope is on the Kansas horizon for women who receive the devastating diagnosis of ovarian cancer, now that federal regulators have approved a Phase I clinical trial for Nanotax, a drug developed by KU researchers. Select area patients are enrolled in the first clinical trials now at the KU Cancer Center, headed by Roy Jensen.
“Nanotax was discovered, developed and will be delivered at clinical trials right here at KU,” Jensen said. “This trial is only the beginning, because our goal is to be the No. 1 academic producer of anti-cancer drugs.”
That would benefit all Kansans by providing world-class treatments for cancers. Additionally, excellent jobs will be available through companies like CritiTech, a Lawrence pharmaceutical firm spun off from KU that would market the drug to patients and their physicians.
